+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effect of pegloticase given by two different methods along with methotrexate in adults with uncontrolled gout. This phase 3 trial compares subcutaneous under the skin injections of pegloticase at 18 mg every two weeks with intravenous into a vein injections of pegloticase at 8 mg every two weeks, both combined with weekly methotrexate. The main goal is to see which approach better maintains low serum uric acid levels during the sixth month. Participants will be randomly assigned to receive either pegloticase by subcutaneous injection or by intravenous infusion, both administered every two weeks, alongside oral methotrexate taken weekly. The trial is double-blind, meaning neither participants nor researchers know which form of pegloticase is given. Methotrexate is given orally concurrently. Treatment continues through at least six months with ongoing evaluations. During the study, participants will have regular assessments to monitor their response to treatment, including blood tests to measure serum uric acid levels and pegloticase concentrations. Safety will be closely observed, including monitoring for injection site reactions, infusion reactions, and anaphylaxis up to 48 weeks. The primary outcome measures participants who maintain normalized uric acid levels during Month 6, with follow-up lasting up to 48 weeks. Total participation may extend to the study completion in June 2028.

Age: 18Years +All GendersPhase 3
75 locations
S

Actively Recruiting

Researchers are evaluating the investigational drug PLG0206 to see if it can help reduce the recurrence of infection in adults who have undergone total knee replacement and are receiving a DAIR Debridement, Antibiotics, and Implant Retention surgical procedure to treat a Prosthetic Joint Infection PJI. This Phase 23 randomized, placebo-controlled study also aims to assess the safety of PLG0206 when used as an irrigation solution during the DAIR procedure. Participants will undergo the DAIR procedure according to their hospitals standard of care. After debridement, they will receive a single dose of either PLG0206 or a placebo as an intra-articular irrigation solution. Following the procedure, all participants will receive standard post-operative care including possible IV or oral antibiotics and will be discharged according to local practices. Participants will be monitored for approximately one year after the procedure for safety and signs of infection recurrence. Study visits will be in-clinic on Days 14, 90, and 365, with additional telephone or virtual visits on Days 30, 180, and 270. Researchers will measure treatment failure rates, safety outcomes, clinical effectiveness, microbiological results, biomarker changes, and functional improvements throughout the study period.

Age: 18Years - 85YearsAll GendersPhase 2Phase 3
21 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations